Our Impact

Celebrating 10 years of progress in amyloidosis care

As we celebrate our 10-year anniversary, we reflect with pride on how far we’ve come — thanks to bold science, relentless commitment, and unwavering donor support. Together, we’ve transformed the amyloidosis research landscape and accelerated lifesaving treatments. But our work is far from done. Join us.

Donate

ARC's Impact

$20M

invested in research & care

With the support of our community, ARC has invested over $20 million in groundbreaking research, clinical innovation, and direct support for people living with amyloidosis.

drug approvals

ARC has helped create an environment where 7 new therapies for amyloidosis have been approved, transforming what’s possible for patients and families.

centers

When ARC was founded, only 5 specialized treatment centers existed — today, there are over 40 expert centers across the U.S., expanding access to knowledgeable care.

reduced time to diagnosis

Through education, awareness, and clinical tools, ARC has helped shorten the time to diagnosis, enabling earlier intervention and better outcomes.

A Decade of Milestones

Patient Focused Drug Development Meeting

Driving FDA understanding of patient experience, to shape drug development, and accelerate approval pathways for amyloidosis.

2015

MAP (My Amyloidosis Pathfinder) empowers patients with personalized guidance to find treatment centers and clinical trial opportunities.

ARC Research Roundtable & Roadmap

Convenes experts to set strategic research priorities and produce a blueprint to accelerate amyloidosis breakthroughs

Voices of Amyloidosis

Captures real-world patient and caregiver insights through targeted surveys to shape research, care, and policy

Onpattro (patisiran) approved

2018

Tegsedi (inotersen) approved

2018

Vyndaqel / Vyndamax (tafamidis) approved

2019

Fosters collaboration between FDA, researchers, clinicians, and industry to advance regulatory science and accelerated therapy development.

2020

Darzalex (daratumumab) approved

2021

Amvuttra (vutrisiran) approved

2022

ATTR QoL Tool

Captures patient-reported quality of life to inform clinical care, trial endpoints, and regulatory decision-making in ATTR

Eplontersen approved

2023

The ARC Amyloidosis Masterclass educates clinicians through expert-led, case-based learning to improve diagnosis, treatment, and care in amyloidosis

ASPIRE (Amyloidosis Stakeholder Partnerships for Impact, Reach & Equity) unites leading partners to improve awareness, diagnosis, care, and health equity for people with amyloidosis.

Attruby (acoramidis) approved

2024

Federated Data Analytics

Enables secure, multi-center data analysis to uncover insights, improve outcomes, and drive amyloidosis research forward

Clinical Fellowships

Trains the next generation of amyloidosis specialists to expand expert care and advance research nationwide

2025

Before finding ARC, I felt lost in a world where few understood amyloidosis or could offer real hope. ARC didn’t just connect me to vital resources; they reminded me I wasn’t fighting this alone. Through their work, I’ve found not only the promise of better treatments, but a community that truly sees and supports patients like me.

— John, amyloidosis patient

VISION FOR THE FUTURE

In the next decade, ARC is committed to transforming the landscape of amyloidosis care. We will expand our work to shorten time to diagnosis, accelerate the development of targeted therapies, and ensure every patient—regardless of geography or background—has access to expert care and reliable information.

Join Us for the Next 10 Years

Every donation accelerates research, brings care closer to patients, and supports life-saving education. Let’s build the next decade—together.

Donate to Fuel the Next Breakthroughs →